Syros Pharmaceuticals, Inc. (0LC7.L)
| Previous close | 5.18 |
| Open | 5.05 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 5.05 - 5.05 |
| 52-week range | 2.27 - 8.10 |
| Volume | |
| Avg. volume | 817 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Syros to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 07, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Details are as follows:
- Business Wire
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
CAMBRIDGE, Mass., May 07, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 14, 2024 to report its first quarter 2024 financial results and provide a corporate update.
- Business Wire
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
CAMBRIDGE, Mass., April 09, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) with RARA overexpression as detected by an FDA approved test
